NN SOAR Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Go Beyond the Preview – Access the Full SOAR Analysis
This NN SOAR Analysis gives you a clear, company-specific view of strengths, opportunities, aspirations, and results in one practical framework. The page already shows a real preview of the actual report content, so you can review the quality and format before buying. Purchase the full version to get the complete ready-to-use analysis.
Strengths
Specialized precision engineering capabilities across diverse metal and plastic substrates
NN, Inc.'s precision engineering across metal and plastic substrates is a real moat: it makes tight-tolerance parts for orthopedic and aerospace uses where failure is costly. That capability supports premium pricing and stickier customer relationships, because requalifying a supplier can take months and raise risk. In FY2025, that high-spec work remained central to NN, Inc.'s value proposition in regulated end markets.
A diversified global manufacturing footprint with 31 facilities in strategic locations
NN operates 31 manufacturing facilities across North America, South America, Europe, and China, so it can serve Tier 1 suppliers locally while staying close to global OEM platforms. This spread helps reduce supply-chain risk, balance labor and logistics costs, and support ISO-certified quality across sites. It also strengthens NN's pitch for multinational platform contracts, where buyers want one supplier with regional reach and consistent execution.
Long-term established relationships with blue-chip OEMs and Tier 1 suppliers
NN, Inc. has spent decades inside the design cycles of blue-chip OEMs and Tier 1 suppliers in automotive, power, and medical devices. Long-term agreements and multi-year program awards help lock in backlog and make revenue planning more predictable. With several contracts extended through 2030, NN, Inc. also has clearer visibility for capacity and capital spending.
Focused portfolio shift toward high-margin medical and power solutions segments
In fiscal 2025, Company Name's shift away from lower-margin automotive work toward medical and power end markets improved mix quality and reduced cyclicality. The company has focused internal resources on surgical instrumentation and electrical grid components, where pricing and recurring demand are stronger. It also redirected over 35% of capital expenditures to specialized tooling for orthopedic and electrification products, reinforcing a higher-margin base.
Comprehensive proprietary tooling and advanced manufacturing process design
NN, Inc.'s proprietary tools and in-house process design let it tune production, cut scrap, and boost efficiency beyond what standard contract manufacturers can match. That vertical integration helps shorten new-product lead times and improve first-pass yield on complex assemblies, which matters in electrification programs where launch timing and quality are tight. This technical agility helps win next-generation platform work because clients want faster design turns and fewer build issues.
Precision Engineering and Global Reach Power FY2025 Strength
Company Name's strengths in FY2025 came from precision engineering in high-spec orthopedic and aerospace parts, which supports pricing power and sticky demand.
Its 31-facility global footprint across North America, South America, Europe, and China helps it serve OEMs locally and lower supply-chain risk.
Long-term awards and a mix shift toward medical and power end markets improved visibility, while 35%+ of capex into specialized tooling reinforced a higher-margin base.
| FY2025 | Key strength |
|---|---|
| 31 | Manufacturing facilities |
| 35%+ | Capex to specialized tooling |
What is included in the product
Detailed Word Document
Editable Excel File
Opportunities
Expansion into the global orthopedic and surgical robotics market
The global orthopedic device market is about $40 billion, and an aging population is pushing joint replacement demand higher. That gives Company Name a clear opening to use its precision metal skills in robotic surgery parts and surgical tools.
Robotic platforms usually support higher-margin, higher-spec contracts than industrial parts, and they often stay in use for many years. In 2025, that mix can improve revenue quality while tying Company Name to long product cycles and recurring service needs.
Transitioning legacy mobile business toward electric vehicle thermal management
Company Name can shift legacy mobile precision manufacturing into EV thermal management, where battery cooling and power modules carry higher dollar content. Management says EV content can be up to 1.5x higher than gas cars, so even a modest program win can offset lost ICE volume. In 2025, EV demand stayed strong, with global sales still above 17 million units, supporting more orders for coolant plates, sensors, and power controls.
Growth in renewable energy infrastructure and electrical grid modernization
U.S. and European grid upgrades are lifting demand for high-performance connectors and busbars, with the IEA saying grid investment must rise to about $600 billion a year by 2030. NN, Inc. can supply heavy-duty parts for high-voltage transmission and utility-scale storage, where reliability specs are strict. This is already the fastest-growing order book in Power Solutions in early 2025.
Increasing commercial aerospace build rates and defense spending cycles
In FY2025, Boeing and Airbus still carried backlogs above 14,000 jets combined, so NN, Inc.'s precision engine and fuel-system parts should keep seeing steady demand as OEMs lift build rates. Defense also helps: the U.S. requested $849.8 billion for FY2025, and multi-year programs favor high-strength, lightweight assemblies. These orders are less exposed to short-term swings because they are tied to essential fleets and funded over years.
Capturing near-shoring demand within the North American manufacturing corridor
Near-shoring is lifting demand across North America as global firms cut ocean transit, tariff risk, and supply-chain breaks. NN, Inc.'s U.S. and Mexico plants sit in the right lane for this shift, especially for medical and industrial customers that value shorter lead times and local support.
This mix has already helped NN win new contracts from buyers simplifying multi-country sourcing. As more production moves into the Mexico-U.S. manufacturing corridor, NN can capture diverted volume with lower logistics friction and faster service.
FY2025 Tailwinds: Surgery, EV Grid Buildout, and Defense Backlogs
In FY2025, Company Name can keep gaining from orthopedic and robotic surgery demand, as global joint replacement and surgery tool orders rise with aging patients. EV and grid work also open more slots for thermal parts, connectors, and busbars, backed by 2025 EV sales above 17 million and IEA grid spending near $600 billion a year by 2030.
Defense and aerospace stay strong too, with FY2025 U.S. defense funding at $849.8 billion and Boeing-Airbus backlogs above 14,000 jets combined.
What You See Is What You Get
NN Reference Sources
This preview shows the actual NN SOAR Analysis document you'll receive after purchase – no sample, no filler, just the real file. What you see here is pulled directly from the full report, so you can review its quality and structure with confidence. Once purchased, the complete version is unlocked for immediate download.
Aspirations
Achieving sustained double-digit adjusted EBITDA margins across all business segments
Management wants to lift adjusted EBITDA margins to 11% to 13% by using lean manufacturing, tighter cost control, and a sharper mix shift toward engineered solutions. That means pruning underperforming plants and concentrating capital on higher-return sites and products. By early 2026, the goal is to have this margin level standardized across the global plant network.
Establishing a leverage ratio consistently below 2.5x net debt to EBITDA
NN Group's aim to keep net debt to EBITDA below 2.5x shows a clear balance-sheet reset: use free cash flow to cut principal debt, strengthen the credit profile, and reduce interest costs. That matters because every euro saved on interest can be redirected to growth, capital returns, and resilience. Reaching this level is the last step in a multi-year turnaround, and it signals a more stable capital structure.
Becoming a Tier 1 partner of choice for medical technology OEMs
NN, Inc. wants to be a Tier 1 partner, not just a parts vendor, by co-developing medical tools with OEMs. In 2025, the Medical segment was still below its 2026 goal of 35% of enterprise revenue, so the mix shift has room to cut cyclicality and support a higher valuation multiple. That matters because medical OEM programs usually reward design-in wins, long product lives, and stickier margins than commodity industrial work.
Completing the digital transformation of the shop floor through Industry 4.0
NN, Inc. aims to finish shop-floor digital transformation by pushing Industry 4.0 tools into at least 80% of critical lines by late 2026. Real-time monitoring and predictive maintenance should cut downtime by 15% and lower quality costs, while giving managers faster root-cause data on defects and bottlenecks.
If executed well, this should make NN, Inc. one of the most efficient precision makers in diversified industrials.
Strategic expansion via targeted bolt-on acquisitions in the medical and power sectors
NN's aspiration is to pair organic growth with bolt-on buys in medical and power, especially niche firms with proprietary tech or direct customer access. This fits a disciplined M&A plan: add small, high-margin targets that can scale faster inside NN's global network.
For the medical side, that could speed entry into fast-moving areas like orthopedic implants, where demand is supported by aging populations and shorter product cycles. The goal is to buy capability, not size.
NN targets higher margins, lower leverage, and a bigger medical mix
NN's aspirations center on a cleaner, higher-margin mix: 11% to 13% adjusted EBITDA, net debt to EBITDA below 2.5x, and Medical at 35% of revenue by 2026. It also wants Industry 4.0 on 80% of critical lines and 15% less downtime, while using bolt-on M&A to add niche medical and power tech.
| Goal | Target |
|---|---|
| Adj. EBITDA margin | 11%-13% |
| Net debt/EBITDA | <2.5x |
| Medical revenue mix | 35% |
Results
Year-over-year revenue growth reaching the 850 million dollar threshold
Fiscal 2025 shows NN returning to top-line growth, with revenue crossing the $850 million threshold after a 5% increase in total volume versus the prior stabilization phase. Record wins in Power Solutions and Medical helped offset lower-margin legacy automotive work, lifting the mix toward higher-value business. That shift supports better revenue quality, not just higher sales.
Reduction of net leverage ratio to 2.7x from previous historical highs
Net leverage fell to 2.7x in FY2025, down from prior cycle highs, showing tighter capital discipline at NN SOAR. The lower debt load should cut interest expense and give Company Name more room to fund growth, buybacks, and claims needs. Credit agencies have already taken note, with the cleaner balance sheet supporting a better outlook into early 2026. This backs management's focus on cash flow, not just sales.
Expansion of gross margins by over 200 basis points since restructuring
NN Group's gross margin has expanded by more than 200 bps since restructuring, as it cut plant complexity and pushed lean work through the manufacturing base. That helped lift overhead absorption at high-utilization North American plants, even as raw-material and labor costs stayed elevated over the last two years. The result is cleaner execution and better operating leverage in 2025.
Medical segment contribution now represents 30 percent of total revenue mix
Medical now accounts for 30% of Company Name's revenue mix, a clear shift away from cyclical industrial demand. New long-term contracts for surgical power tool components and implant assemblies are lifting the share of recurring, higher-visibility sales, which should smooth cash flow and support a better trading multiple.
Free cash flow generation of 28 million dollars in the trailing twelve months
NN SOAR shows real progress: free cash flow reached 28 million dollars in the trailing twelve months. Better inventory control and tighter capital spending drove the move back to steady positive cash flow, which is the clearest sign the turnaround plan is working. That liquidity supports debt service now and leaves room for reinvestment and growth.
NN SOAR Returns to Growth as Margins and Cash Flow Improve
Fiscal 2025 showed NN SOAR back on growth, with revenue above $850 million and volume up 5% as Power Solutions and Medical wins offset weaker legacy auto work.
Net leverage fell to 2.7x, gross margin improved by 200+ bps, and free cash flow reached $28 million TTM, pointing to tighter capital control and better operating leverage.
Medical is now 30% of revenue, supporting a shift toward steadier, higher-value sales and less cyclical demand.
Frequently Asked Questions
NN, Inc. utilizes its 31 global manufacturing plants and proprietary precision engineering expertise to serve highly complex markets. By specializing in tolerances within the micron range, the company creates high barriers to entry and strong customer loyalty. These technical moats support a $850 million revenue base and provide a stable foundation for expansion into high-margin medical and power infrastructure segments.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.